Table 1.

—Demographics and Clinical Characteristics of Patients With Pseudomonas aeruginosa CAP (N = 402) With or Without Initial Macrolide Therapy

Characteristic	Nonmacrolide (n = 231)	Macrolide (n = 171)	P Value
Age, y	76.1 ± 6.5	77.4 ± 6.1	.04
Male sex	227 (98.3)	171 (100)	.1
Married	117 (50.6)	93 (54.4)	.4
Race
White	186 (80.5)	152 (88.9)	.02
Black	19 (8.2)	11 (6.4)	.5
Smoker	89 (38.5)	69 (40.4)	.7
Alcohol abuse	11 (4.8)	7 (4.1)	.8
Comorbid conditions
Myocardial infarction	7 (3.0)	5 (2.9)	.9
Chronic heart failure	35 (15.2)	34 (19.9)	.2
Peripheral vascular disease	29 (12.6)	19 (11.1)	.7
Cerebrovascular disease	35 (15.2)	21 (12.3)	.4
Dementia	7 (3.0)	10 (5.8)	.2
COPD	160 (69.3)	121 (70.8)	.8
Rheumatologic disease	4 (1.7)	5 (2.9)	.5
Peptic ulcer	5 (2.2)	3 (1.8)	.9
Cirrhosis	2 (0.9)	3 (1.8)	.6
Diabetes mellitus	50 (21.6)	34 (19.9)	.7
Diabetes with complications	11 (4.8)	14 (8.2)	.2
Hemiplegia or paraplegia	3 (1.3)	1 (0.6)	.6
Chronic renal disease	3 (1.3)	4 (2.3)	.4
Neoplastic disease	45 (19.5)	37 (21.6)	.6
Metastatic disease	7 (3.0)	6 (3.5)	.7
Charlson comorbidity index score	2.2 ± 1.9	2.4 ± 2.0	.2
Medication prescription within 90 d
Cardiovascular medications	2.2 ± 1.2	2.1 ± 1.1	.3
Antidiabetic medications	1.3 ± 0.6	1.3 ± 0.5	.8
Pulmonary medications	3.9 ± 1.7	3.7 ± 1.8	.4
P aeruginosa antibiotic coverage	205 (88.7)	154 (90.1)	.6
Category of antibiotics
β-Lactams	171 (74.0)	129 (75.4)	.7
Aztreonam	10 (4.3)	7 (4.1)	.9
Aminoglycosides	71 (30.7)	50 (29.2)	.7
Fluoroquinolones	150 (64.9)	109 (63.7)	.8

Data are presented as mean ± SD or No. (%). CAP = community-acquired pneumonia.